

# Factors Associated with Non-Adherence to Antiretroviral Therapy among Adults living with HIV/AIDS in Arsi Zone, Oromia

Dibaba B<sup>1\*</sup> and Hussein M<sup>2</sup>

<sup>1</sup>College of Health Sciences, Department of Public Health, Asella, Ethiopia

<sup>2</sup>Department of Pharmacy, Arsi University, Asella, Ethiopia

## Abstract

**Objective:** To assess factors associated with non-adherence to antiretroviral therapy among adults living with HIV/AIDS in Arsi zone.

**Methods:** This is a multiple facility-based cross-sectional study, where 306 adult aged over 18 years who were receiving antiretroviral therapy had interviewed using a structured questionnaire about their experience of taking antiretroviral therapy between June 1, 2015-June 1, 2016. Additional data was extracted from each facilities record. Participants were defined as non-adherent if they missed at least one dose of their highly active antiretroviral therapy prescriptions within the last 30 days. Participants were also asked to indicate reasons for missing doses of highly active antiretroviral therapy. Descriptive analysis and Multivariable logistic regression model was used to determine predictors of non-adherence. The odds ratios in the binary logistic regression along with 95% confidence interval were used.

**Results:** Overall, 306 clients responded; 35% were non-adherent. Seventy five (24.5%) and 214(69.9%) patients agreed and strongly agreed that the use of antiretroviral therapy is essential in their life. Thirty seven (12.1%) do not know whether drug resistance develop when antiretroviral therapy are missed or not. The reasons for missing doses include forgetting 71 (23.2%) and hiding from colleagues 90 (29.4%). Respondents who reported hiding from colleagues were found to be 2 times more likely to be non-adherent to antiretroviral therapy compared to respondents who had not reported hiding from colleagues (adjusted odds ratio=2.02; 95% Confidence interval: 1.19-3.43).

**Conclusion:** Prevalence of non-adherence to antiretroviral therapy is high. Some of the respondents do not know whether drug resistance develop when antiretroviral therapy are missed or not. Forgetfulness and hiding from colleague were the most common reason for missing doses. Hence, antiretroviral therapy counselors need to emphasis on memory aids. Creation of awareness on the risks of non-adherence is needed.

**Keywords:** Non-adherence; Antiretroviral therapy; HIV/AIDS care; Arsi zone, Oromia

## Introduction

Antiretroviral therapy has been initiated to combat human immunodeficiency virus (HIV)/acquired immune-deficiency syndrome (AIDS). Antiretroviral therapy use has slowed disease progression, decreased mortality and improved the quality of life for many persons with HIV [1,2]. Antiretroviral therapy has improved the health of many human immunodeficiency virus (HIV) positive individuals who otherwise would have died. Treatment efficacy relies, however, on sustained adherence, which constitutes a serious challenge to those receiving antiretroviral therapy [3]. The regimens are often complicated and can include varying dosing schedules, dietary restrictions, and adverse effects [4]. Consistently high levels of adherence are necessary for reliable viral suppression [5] and prevention of resistance [6], disease progression, and death [7]. Even though antiretroviral therapy is the single most dramatic development yet in the treatment of HIV/AIDS, many have been described as inconsistent with their treatment regimens [8,9].

Non-adherence is a risk factor for development of drug resistance [10]. A study done in China, Hunan Province found that all patients on antiretroviral therapy who reported missing a dose in the last 7 days had drug resistance mutations [6]. A study done in Swiss indicated that there was a significant association between optimal viral suppression and non adherence as well as a significant linear trend in optimal viral suppression by missed doses [11]. A study done in Swiss in 2015 explored the effect of non-adherence to antiretroviral therapy and

found that the risk of viral failure (fail to suppress the virus) increased with each self-reported missed dose per 4 weeks and Self-report of two or more missed doses of antiretroviral therapy is associated with an increased risk of both viral failure and death [12].

Available data suggests that patients must take a high proportion (95% or more) of antiretroviral drug doses to maintain suppression of viral replication [13,14]. However, many studies reported that a number of patients took less than 95% of antiretroviral therapy [8,9]. A study done in southwest Ethiopia in 2008 found that the prevalence of non adherence to antiretroviral therapy was 21% [15]. A study done in northwest Ethiopia in 2010 indicated that the prevalence of non-adherence was 17.3% [16]. A study done in Nigeria in 2008 found that the prevalence of non-adherence to antiretroviral therapy among adult person living with HIV/AIDS was 37.1% [17]. A study done in Yaoundé, Cameroon in 2013 showed that the prevalence of non-adherence to

**\*Corresponding author:** Bekele Dibaba (MPH), Lecturer in Arsi University, College of Health Sciences, Department of Public Health, Asella, Ethiopia, Tel: +2510910955032; E-mail: [fenetbekele@gmail.com](mailto:fenetbekele@gmail.com)

**Received** November 30, 2016; **Accepted** December 14, 2016; **Published** December 21, 2016

**Citation:** Dibaba B, Hussein M (2017) Factors Associated with Non-Adherence to Antiretroviral Therapy among Adults living with HIV/AIDS in Arsi Zone, Oromia. J AIDS Clin Res 8: 647. doi:10.4172/2155-6113.1000647

**Copyright:** © 2017 Dibaba B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

antiretroviral therapy was 34.9% [18]. These rates of non adherence can contribute to sub-optimal drug levels which can lead to drug resistance and increase mortality. One of the main factors contributing to sub-optimal drug levels and resistance is non-adherence to treatment [19].

Understanding factors associated with poor adherence is essential to maximize virologic suppression and reduce mortality. Non adherence to antiretroviral therapy has been associated to diverse factors including patient related factors, health condition/disease, health care system/health care team, therapy/treatment and socio-economic factors [20-22]. Reasons for non-adherence are multi factorial. Age (younger), perceived treatment side effects, dosing frequency different from twice daily, a protease inhibitor-based regimen, depression and lack of support from the main partner were associated with non-adherence [23]. Similarly, a study done in Kenya found that younger respondents between 25 and 49 ages were more likely not to be non-adherent to highly active antiretroviral therapy [24]. Likewise, study done in selected hospitals from south and central Ethiopia found that being unmarried was associated with non-adherence [25].

A study done in Nepal indicated that the major reason for non-adherence was side effect of antiretroviral therapy drugs [26]. However, study done in North-West Ethiopia found that among reasons for missing doses were forgetfulness 29 (43.3%) and side-effect of antiretroviral therapy drugs 2 (3%) [27].

The above studies signified that the magnitudes of factors responsible for non adherence were dissimilar in different settings and different factors were associated with non adherence in dissimilar study area. Moreover, published data about factors that influence non-adherence to antiretroviral therapy in Oromia is limited. To generate this knowledge, this study determined factors associated with non adherence in Arsi zone, Oromia.

## Literature Review

### Prevalence of non-adherence to antiretroviral therapy

Antiretroviral therapy requires high-level (>95%) adherence. However, non-adherence becomes a challenge. Significant proportions of HIV/AIDS patients attending the care do not reach high levels of adherence leading to viral resistance to the drug. A study done in Yaoundé, Cameroon in 2013 showed that the prevalence of non-adherence to antiretroviral therapy was 34.9% (18). A study done in Nigeria in 2008 found that the prevalence of non-adherence to antiretroviral therapy among adult person living with HIV/AIDS was 37.1% [17]. The prevalence non-adherence in Southwest Ethiopia in 2008 was 21% [15] and 22% in Cote d'Ivoire [28]. A study done in Northwest Ethiopia in 2010 found that the prevalence of non-adherence was 17.3% [16].

### Socio-demographic factors and non-adherence to antiretroviral therapy

Understanding factors associated with poor adherence is essential to maximize virology suppression and reduce mortality [29]. Factors associated with non-adherence varies with gender [30]. Study done among Brazilian patients indicated that the incidence of non-adherence was 1.5 times greater among women compared to men [31]. A study done in Kenya found that younger respondents between 25 and 49 ages were more likely not to be non-adherent to highly active antiretroviral therapy although age did not predict [24]. Similarly, younger individuals were associated with poor adherence [32]. Study done in selected hospitals from south and central Ethiopia found that being

unmarried and alcohol drinking were associated with non-adherence [25]. However, a study found no association was observed between non-adherence to antiretroviral therapy and gender, age, marital status and educational level [33].

Employment status was associated with poor adherence and this may be corroborated by the major reason reported for non-adherence (busy at work or school) [34]. Living in isolation were significantly associated with non-adherence to antiretroviral therapy [35].

Study done in Kenya found that respondents who accessed therapy in clinics within a walking distance (5KM) from their homes were associated with non-adherence. These findings together with social stigma associated with antiretroviral therapy use suggested that most respondents who accessed free therapy in clinics within walking distance to their homes did so due to lack of choice; speculatively, could not afford transport cost to alternative health facility where antiretroviral therapy is given [24].

### Reasons for non-adherence to antiretroviral therapy

A study done in Nigeria in 2013 indicated that common reasons for non-adherence were living far away from the medical centre (8.1%) [36]. A study done in North-West Ethiopia showed that the reasons for missing doses were forgetfulness (43.3%) and side-effect of antiretroviral therapy drugs (3%) [27]. Study done in Addis Ababa, Ethiopia showed that the major reasons for non-adherence include simply forgot which was 33.9% [37]. Similarly, a study done in Harari showed that main reasons for non-adherence were forgetting (47.2%) [38]. Likewise, study done in Nigeria in 2013 found that common reasons for non-adherence were forgetfulness (51.5%) [36]. Study done in Tanzania showed that reasons for non-adherence were side effects of antiretroviral therapy drugs which was 53.3% and the side effects antiretroviral therapy drugs were found to be statistically significant [39]. Study done in Nepal indicated that among the reasons for non-adherence, side effect of antiretroviral therapy drug were mentioned [26].

### Side effects of antiretroviral drugs and non-adherence

Non-adherence was independently associated with side effects of antiretroviral drugs [40]. Similarly, self-report of three or more adverse reactions were associated with an increased risk of non-adherence [41]. Likewise, medication side effects were a significant predictor of non-adherence in the sample at large and among women in particular [42]. Study done in Brazil in 2015 showed that adverse drug reaction was associated with non-adherence [43].

### Alcohol drinkers and non-adherence to antiretroviral therapy

Study done in West Africa found association between hazardous drinkers and non-adherence [44]. Similarly, study done in Cameroon found that drinking alcohol was associated with non-adherence [9]. Alcohol use was associated with non-adherence to antiretroviral therapy among HIV infected people in Pwani Region, eastern Tanzania [45]. Likewise, study done in South Africa showed that alcohol use is independently associated with antiretroviral adherence [46]. Study done in South India also indicated the association of alcohol use with non-adherence [47]. Similarly, alcohol dependence was a significant predictor of non-adherence only in women [42]. Alcohol use were associated with an increased risk of non-adherence [41].

### Depression and non-adherence to antiretroviral therapy

Study done in Southwest Ethiopia found that patients who were not depressed were two times more likely to be adherent than those who

were depressed [15]. Similarly study done in United States indicated that being younger and greater risk of depression were associated with poorer adherence [48]. Likewise, study done in Nigeria among depressed HIV/AIDS patients indicated that depressive disorder in patients with HIV/AIDS is associated with poor adherence to antiretroviral medication [49]. A study done in South India indicated that depression was associated with lower adherence [50].

## Methodology

### Setting

This study was conducted in Arsi zone health facilities where antiretroviral therapy is given. Arsi zone located is in Oromia National Regional State. Arsi zone is 175 kilo-meter away from capital city of Ethiopia (Addis Ababa).

### Study population and period

The study populations were HIV+ outpatients aged 18 years or more on free antiretroviral therapy for three or more months. The study was carried out between June 1, 2015-June 1, 2016.

### Study design

Multiple facility-based cross-sectional observational study design

### Sample procedure and sample size calculation

There were 29 health facilities which give antiretroviral service in Arsi zone (study setting). Out of the 29 health facilities 10 were randomly selected using lottery method. Then, the sample size was calculated using EPIINFO version: 7.2.0.1 STATCALC taking the average prevalence of non-adherence from recently done studies in different setting which was 23.7%, a precision of 5% and with 95% confidence level. After adding 10% for non-response rate, an overall sample size of 306 was obtained. Next, the calculated sample size was proportionally allocated to each of the health facilities based on the number of clients on antiretroviral therapy in each of the health facilities. Later, systematic sampling methods were used to select the study subjects. That is, the number of clients on antiretroviral therapy in each of the health facility were divided to by the sample size proportional to every of the health facilities to get the interval and every that interval the study participants were selected as they visited the health facilities.

### Data collection method

Data was collected from systematically selected persons attending HIV/AIDS care as they visited the health facilities for their antiretroviral treatment. Data on variables including non-adherence and associated factors were collected using an interviewer administered pretested questionnaire. The patients were interviewed about their highly active antiretroviral therapy beliefs, antiretroviral therapy intake and reasons for non-adherence. Additional data about the respondents' antiretroviral intake were extracted from hospital records.

### Data analysis and management

Data generated from the questionnaire were entered into EPIINFO version 7.1.0.1 and exported to SPSS version 21 for analysis. Participants were defined as non-adherent if they missed at least one dose of their highly active antiretroviral therapy prescriptions within the last 30 days. Participants were also asked to indicate reasons for missing doses of highly active antiretroviral therapy. Descriptive statistics was done to assess basic client characteristics and proportion of non-adherence. Frequencies, cross-tabulations, chi-square test, and multivariate logistic

regression were used to determine predicting factors. Binary logistic regression was done to determine statistical association between explanatory variables and non-adherence. All variables that were associated with non-adherence in binary logistic regression analyses were entered into multivariable logistic regression. P-values at the level of significance of 5% were considered statistically significant.

### Operational definition

Non adherence is defined as self reported at least one missed doses of antiretroviral therapy in the last 30 days. This definition was generated because of fail to suppress the virus occurred among the patients who missed one dose per 4 weeks [12]. Moreover, other studies have used this definition to study non adherence [11,24].

### Ethical considerations

Ethical clearance was given by Arsi University Ethical Review Committee, and permission to conduct the research was obtained from the participating health facilities. Consent was obtained both verbally and in written. To ensure confidentiality, interviews were conducted in private and strict control maintained over data.

## Results

### Socio-demographic characteristics of the respondents

Out of the 306 patients interviewed, all of them answered almost all the adherence questions and 35.2% were non-adherent. Males were 139 (45.4%) and females 167 (54.5%); their age were 18+ years. One hundred fifty (49%) had primary education and 95 (31%) had secondary education. Two hundred six (67.3%) respondents earned less than 500 EBR per month and 71 (23.2%) had monthly income of 501-1000. Majority respondents 224 (73.2%) had a current CD4 count of more than 200 cells/ml (mean CD4 count of 524.12). The initial mean CD4 count was 266.76. Most 252(82.4%) patients lived with family and 48(15.7%) live alone. Two hundred twenty two (72.5%) reported getting social support (Table 1).

### Reasons for not taking antiretroviral therapy

Among the reasons for missing doses were forgetting 71 (23.2%), hiding from colleagues 90 (29.4%), drink alcohol 62(20.3%) and side effect of antiretroviral therapy drugs 59 (19.3%) (Table 2).

### Knowledge and belief about taking antiretroviral therapy medication

Seventy five (24.5%) and 214 (69.9%) patients agreed and strongly agreed that the use of antiretroviral therapy is essential in their life. Respondents those agreed and strongly agreed that missing doses will determine the treatment were 70 (22.9%) and 105(34.3%) respectively. Similarly respondents who agree and strongly agree that drug resistance develops when antiretroviral are missed were 92(30.1%) and 163(53.3%) The time at which the medication is taken will influence its effectiveness were agreed and strongly agreed by respondents 122 (39.9%) and 160(52.3%) (Table 3).

### Association between Socio-demographic variables and non-adherence to antiretroviral therapy

Multivariable logistic regression showed that there is no significant association between some socio-demographic variables and non-adherence to antiretroviral therapy at P-value of <0.05 (Table 4).

### Association between reasons for not taking antiretroviral

Variables		Non-adherence				Total	
		Yes		No			
		Frequency	%	Frequency	0%	Frequency	%
Gender	Male	46	43.0	93	46.7	139	45.4
	Female	61	57.0	106	53.3	167	54.6
	Total	107	100.0	199	100.0	306	100.0
Age group	18-19	0	0	2	1.0	2	0.7
	20-24	2	1.90	5	2.5	7	2.3
	25-49	92	86.0	170	85.4	262	85.6
	>=50	13	12.1	22	11.1	35	11.4
	Total	107	100.0	199	100.0	306	100.0
Marital status	never married	67	6.5	134	9.0	201	8.2
	married	24	62.6	30	67.3	54	65.7
	divorced/separated	9	22.4	17	15.1	26	17.6
	widow/widower	107	8.40	199	8.5	306	8.5
	Total		100.0		100.0		100.0
Educational level	No Education	2	1.9	5	2.5	7	2.3
	Primary school	59	55.1	91	45.7	150	49.0
	Secondary school	30	28.0	65	32.7	95	31.0
	High school	14	13.1	30	15.1	44	14.4
	vocational training	2	1.9	7	3.5	9	2.9
	University	0	0	1	0.5	1	0.3
	Total	107	100.0	199	100.0	306	100.0
Monthly income	<500	76	71.0	130	65.3	206	67.3
	501-1000	24	22.4	47	23.6	71	23.2
	1001-1500	5	4.7	16	8.0	21	6.9
	1501-2000	0	-	4	2.0	4	1.3
Monthly income	>2000	2	1.9	2	1.0	4	1.3
	Total	107	100.0	199	100.0	306	100.0
Living with	alone	17	15.9	31	15.6	48	15.7
	family	87	81.3	165	82.9	252	82.4
	other	3	2.8	3	1.5	6	2.0
	Total	107	100.0	199	100.0	306	100.0
Use reminder	Yes	93	86.9	188	91.8	25	8.2
	No	14	13.1	11	5.5	261	85.3
	Total	107	100.0	199	100.0	306	100.0
	not at all	2	1.9	3	1.5	5	1.6
Level of reminder helped you	a little	9	8.4	1	0.5	10	3.3
	some what	17	15.9	34	17.1	51	16.7
	a lot	65	60.7	146	73.4	211	69.0
	Total	107	100.0	199	100.0	306	100.0
How often did you follow dietary instruction	always	27	25.2	102	51.3	129	42.2
	some time	76	71.0	93	46.7	169	55.2
	rarely	1	0.9	0	0	1	0.3
	never	3	2.8	4	2.0	7	2.3
	Total	107	100.0	199	100.0	306	100.0
Clinical character	Mean CD4 count	Non adherent			Adherent		
		Mean	Frequency	%	Mean	Frequency	%
	Initial	117.4	74	34.1	176.1	143	65.9
	current	183.4	78	34.8	340.7	146	65.2

Table 1: Socio-demographic and clinical characteristics versus status of non-adherence among adults living with HIV/AIDS in Arsi zone, South-East Oromia, June 1, 2015-June1, 2016.

### therapy and non-adherence to antiretroviral therapy

Multivariable logistic regression showed that there is significant association between non-adherence to antiretroviral therapy and reasons for not taking antiretroviral therapy. Patients who had accessing antiretroviral therapy in a clinic within walking distance or <5 km from

home were found to be 1.7 times more likely to be non-adherent to antiretroviral therapy compared respondents who were far away from clinic or >5 km (adjusted odds ratio=1.73; 95% Confidence interval: 1.06-2.82). Likewise, patients who reported hide from colleagues were found to be 2 times more likely to be non-adherent to antiretroviral therapy compared to respondents who had not reported hide from

colleagues (adjusted odds ratio=2.02; 95% Confidence interval: 1.19-3.43) (Table 5).

## Discussion

In this study the prevalence of non-adherence to antiretroviral therapy among adult person living with HIV/AIDS is 35%. Consistent to our finding study done in Yaoundé, Cameroon in 2013 showed that the prevalence of non-adherence to antiretroviral therapy was 34.9% [18]. Study done in Nigeria in 2008 found that the prevalence of non-adherence to antiretroviral therapy among adult person living with

HIV/AIDS was 37.1% [17]. A study done in southwest Ethiopia in 2008 indicated that the prevalence of non-adherence was 21% [15]. Similarly, a study done in northwest Ethiopia in 2010 found that the prevalence of non-adherence was 17.3% [16]. The inconsistency with these findings could be attributed to differences in assessment methods and treatment periods when antiretroviral therapy knowledge among patients and clinicians was low.

In this study no significant association seen between non-adherence to antiretroviral therapy among adult person living with HIV/AIDS and gender, age, marital status and educational level. Similarly, a study done in 2009 reported that no association was observed between non-adherence to antiretroviral therapy and gender, age, marital status and educational level [33]. However, study done in Kenya in 2011 found that younger respondents between 25 and 49 ages were more likely not to be non-adherent to highly active antiretroviral therapy [24]. A study done in 2007 showed that younger individuals were associated with poor adherence [32]. Better adherence among older adults may be explained by survivor effect in that, individuals who maintain greater compliance with treatment recommendations may actually outlive those who are non-adherent.

In our study marital status and alcohol use were not significantly associated with non-adherence to antiretroviral therapy among adult person living with HIV/AIDS. However, a study done in 2009 in selected hospitals from south and central Ethiopia found that being unmarried and alcohol drinking were associated with non-adherence [25]. This inconsistency could be due to differences in study periods.

In this study respondents who accessed therapy in clinics within a walking distance (5 km) from their homes were about 1.7 times more likely to be non-adherent than those who were far away from health facility where antiretroviral therapy is given (>5 km). Similarly, a study done in Kenya in 2011 indicated that accessing antiretroviral therapy in

Variable		Frequency	Percent
Drink alcohol	no	244	79.7
	yes	62	20.3
	Total	306	100.0
Felt depressed	no	255	83.3
	yes	51	16.7
	Total	306	100.0
Felt sick	no	251	82.0
	yes	55	18.0
	Total	306	100.0
Being busy and forgot	no	235	76.8
	yes	71	23.2
	Total	306	100.0
side effects	no	247	80.7
	yes	59	19.3
	Total	306	100.0
Hide from colleagues	no	216	70.6
	yes	90	29.4
	Total	306	100.0

**Table 2:** Reasons for not taking antiretroviral therapy among adults living with HIV/AIDS in Arsi zone, South–East Oromia, June 1, 2015-June1, 2016.

Variable		Frequency	Percent
I will take antiretroviral therapy for the rest of my life	agree	75	24.5
	disagree	1	.3
	strongly agree	214	69.9
	Total	306	100.0
Missing doses will determine if treatment works	agree	70	22.9
	don't know	12	3.9
	strongly agree	105	34.3
	Total	306	100.0
Drug resistance develop when antiretroviral are missed	agree	92	30.1
	don't know	37	12.1
	strongly agree	163	53.3
	Total	306	100.0
Some antiretroviral have to be taken with empty stomach others with food	agree	133	43.5
	disagree	2	.7
	don't know	10	3.3
	strongly agree	145	47.4
	Total	306	100.0
The time at which the medication is taken will influence its effectiveness	agree	122	39.9
	don't know	9	2.9
	strongly agree	160	52.3
	Total	306	100.0

**Table 3:** Knowledge and belief towards taking antiretroviral therapy among adults living with HIV/AIDS in Arsi zone, South–East Oromia, June 1, 2015-June1, 2016.

Variables		Non-adherence				95% Confidence interval for crude odds ratio	95% Confidence interval for adjusted odds ratio
		Yes		No			
		Frequency	%	Frequency	%		
Gender	male	46	33.1	93	66.9	1.97 (1.38-2.79)*	0.99 (0.59-1.68)
	female	61	36.5	106	63.5	1	1
age	18-19	0	0	2	100.0	7.39 (0.10-532.23)	4.42 (0.52-373.15)
	20-24	2	28.6	5	71.4	2.36 (0.47-11.90)	1.24 (0.19-7.82)
	25-49	92	35.1	170	64.9	1.81 (1.41-2.34)*	1.15 (0.54-2.48)
	>=50	13	37.1	22	62.9	1	1
Marital status	never married	67	28.0	134	72.0	2.41 (1.02-5.70)*	1.49 (0.43-5.15)
	married	24	33.3	30	66.7	1.95 (1.46-2.61)*	1.09 (0.44-2.65)
	divorced	9	44.4	17	55.6	1.25 (0.73-2.14)	0.81 (0.29-2.23)
	widow	107	34.6	199	65.4	1	1
Educational level	No Education	2	28.6	5	71.4	2.50 (0.48-12.90)	1.10 (0.10-11.21)
	Primary school	59	39.3	91	60.7	1.53 (1.10-2.13)*	0.63 (0.12-3.29)
	Secondary	30	31.6	65	68.4	1.54 (1.11-2.14)*	0.89 (0.17-4.61)
	High school	14	31.8	30	68.2	2.16 (1.40-3.33)*	0.70 (0.12-4.01)
	College/v	2	22	8	80	1	1
Monthly income	<500	76	36.9	130	63.1	1.71 (1.28-2.27)*	0.69 (0.10-4.50)
	501-1000	24	33.8	47	66.2	1.95 (1.19-3.20)*	0.76(0.11-5.18)
	1001-1500	5	23.8	16	76.2	3.20(1.17-8.73)*	1.08(0.13-8.55)
	>1500	2	25.0	6	75.0	1	1
Living with	Live alone	17	35.4	31	64.6	1.79 (0.99-3.23)	1.87 (0.34-10.12)
	family	87	34.5	165	65.5	1.86 (1.43-2.41)*	1.63 (0.32-8.19)
	other	3	50.0	3	50.0	1	1

**Table 4:** Association between some socio-demographic variables and non-adherence to antiretroviral therapy among adults living with HIV/AIDS in Arsi zone, South-East Oromia, June 1, 2015-June 1, 2016.

\*Statistically significant in crude odds ratio: P-value <0.05

Variables		Non-adherence				95% Confidence interval for crude odds ratio	95% Confidence interval for adjusted odds ratio
		Yes		No			
		Frequency	%	Frequency	%		
Distance from health facility	<5 km	30	30.9	67	69.1	2.23 (1.45-3.43)*	1.73 (1.06-2.82)**
	>5 km	77	36.8	132	63.2	1	1
Forget	yes	31	43.7	40	56.3	1.29 (0.81-2.06)	0.35 (0.14-0.88)
	no	76	32.3	159	67.7	1	1
Side-effects	yes	22	50.0	37	50.0	1.00 (0.14-7.09)	0.32 (0.04-2.83)
	no	85	34.8	162	65.2	1	1
How often did you drink alcohol	daily >3	1	33.3	2	66.7	2.00 (0.18-22.06)	1.66 (0.14-18.92)
	daily <3	8	88.9	1	11.1	0.13 (0.02-0.99)	0.07 (0.01-0.61)
	weekly <5	3	60.0	2	40.0	0.67 (0.11-3.99)	0.67 (0.09-4.63)
	occasionally	6	31.6	13	68.4	2.17 (0.82-5.70)	1.77 (0.62-5.05)
	rarely occasionally	26	34.7	49	65.3	1.89 (1.17-3.02)*	1.47 (0.86-2.51)
Hide from colleagues	never	63	32.3	132	67.7	1	1
	yes	27	29.9	63	70.1	1.70 (1.29-2.24)*	2.02 (1.19-3.43)**
depressed	no	80	37.0	136	63.0	1	1
	yes	16	31.4	35	68.6	2.19 (1.21-3.95)*	5.43 (0.89-33.06)
sick	no	91	35.7	164	64.3	1	1
	yes	19	34.5	36	65.5	1.89 (1.09-3.30)*	0.93 (0.19-4.54)
no	no	88	35.1	163	64.9	1	1

**Table 5:** Association between non-adherence and reasons for not taking antiretroviral therapy among adults living with HIV/AIDS in Arsi zone, South-East Oromia, June 1, 2015-June 1, 2016.

\*Statistically significant in crude odds ratio: P-value <0.05. \*\*Statistically significant in adjusted odds ratio: P-value <0.05

a clinic within walking distance from home (OR=2.387, CI.95=1.155-4.931; p=0.019) predicted non-adherence [24]. These findings together with social stigma associated with antiretroviral therapy use suggested that most respondents who accessed free therapy in clinics within walking distance to their homes did so due to lack of choice; speculatively, could not afford transport cost to alternative health

facility where antiretroviral therapy is given. Inconsistency to our finding, study done in Nigeria in 2013 indicated that common reasons for non-adherence were living far away from the medical centre (8.1%) [36]. The Inconsistency could be due to difference in socio-cultural factors among the study settings.

In this study 75 (24.5%) and 214 (69.9%) patients agreed and

strongly agreed that the use of antiretroviral therapy is essential in their life. However, study done in North-West Ethiopia in 2015 found that 340 (96.9%) patients agreed and strongly agreed that the use of antiretroviral therapy is essential in their life [27]. The inconsistency could be due to difference in awareness among person living with HIV/AIDS at the two study settings. That is, the participants of the northwest Ethiopia study were hospitalized patients who might have more awareness about the use of antiretroviral therapy.

In this study among the reasons for missing antiretroviral therapy doses were forgetting 71 (23.2%) and side effect of antiretroviral therapy drugs 59 (19.3%). Similarly, a study done in North-West Ethiopia indicated that the reasons for missing doses were forgetfulness 29 (43.3%) and side-effect of antiretroviral therapy drugs were 2 (3%) (27). Likewise, a study done in Addis Ababa, Ethiopia showed that the major reasons for non-adherence include simply forgot (33.9%) (37). A study done in Harari showed that main reasons for non-adherence were forgetting (47.2%) (38). Likewise, study done in Nigeria in 2013 found that common reasons for non-adherence were forgetfulness (51.5%) [36].

In our study the adverse effects antiretroviral therapy reported by the respondents did not significantly influence non-adherence. However, Study done in Brazil in 2015 showed that adverse drug reaction was associated with non-adherence [43]. A study done in Tanzania in 2011 showed that reasons for non-adherence were side effects of antiretroviral therapy drugs which was 53.3% and the side effects antiretroviral therapy drugs were found to be statistically significant [39]. Similarly, a study done in 2009 indicated that non-adherence was independently associated with side effects of antiretroviral drugs [40]. Likewise, study done in 2005 showed that self-report of three or more adverse reactions were associated with an increased risk of non-adherence [41]. The possible explanations have to be explored.

In this study drinking alcohol was not associated with non-adherence to antiretroviral therapy. However, study done in Cameroon found that drinking alcohol was associated with non-adherence [9]. A study done in South India also indicated the association of alcohol use with non-adherence [47]. A study done in London showed that alcohol use were associated with an increased risk of non-adherence [41]. The inconsistency could be due to differences in study settings.

Our study indicated that depression was not significantly associated with non-adherence to antiretroviral therapy. However, a study done in Nigeria among depressed HIV/AIDS patients indicated that depressive disorder in patients with HIV/AIDS is associated with poor adherence to antiretroviral medication [49]. A study done in South India indicated that depression was associated with lower adherence [50]. This inconsistency may be due to differences in proportion of depressed patients among the studies.

## Conclusion

The above studies indicated that the magnitudes of factors responsible for non adherence were dissimilar in different settings. Similarly, the above studies had pointed out that different factors have been associated with non adherence to antiretroviral therapy in different settings though there are few similarities. Given a complex array of factors associated with non adherence, no single strategy is likely to be effective for every patient who is non adherent to antiretroviral therapy. Our study has determined the major factors associated with non adherences which include hiding from colleague and forgetfulness. So, strategy to reduce non adherence in the study area can focus on these factors.

The finding of this study should be interpreted with some limitations because our measurement of non adherence was only based on participants' declaration of missed doses. Recall bias was also the possible bias that may encounter this study. Despite the above limitations, the study addressed several variables that predict non adherence and to fully characterize the study population, we extracted additional data from participants' record.

## Acknowledgement

Our deepest gratitude goes to all data collectors and Respondents. Our sincere appreciation goes to our family for their time and continuous encouragement during the whole period of this work.

## Authors Contribution

Bekele Dibaba carried out the research from conception to the write up of the final article. Mohammed Hussein is a principal researcher. He was participated in developing the proposal and supervised during data collection.

## References

1. Okonji JA, Zeh C, Weidle PJ, Williamson J, Akoth B, et al. (2012) CD4, viral load response, and adherence among antiretroviral-naïve breast-feeding women receiving triple antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV in Kisumu, Kenya. *J Acquir Immune Defic Syndr* 61: 249-257.
2. Knobel H, Guelar A, Carmona A, Espona M, Gonzalez A, et al. (2001) Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. *AIDS Patient Care STDS* 15: 193-199.
3. Meresse M, March L, Kouanfack C, Bonono RC, Boyer S, et al. (2014) Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon. *HIV Med* 15: 478-487.
4. Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM, Bimirew MA, et al. (2012) Barriers and facilitators of adherence to antiretroviral drug therapy and retention in care among adult HIV-positive patients: A qualitative study from Ethiopia. *PLoS One* 9: e97353.
5. Lamiraud K, Moatti JP, Raffi F, Carrieri MP, Protopopescu C, et al. (2012) Adherence to and effectiveness of highly active antiretroviral treatment for HIV infection: Assessing the bidirectional relationship. *Med Care* 50: 410-418.
6. Chen X, Zou X, He J, Zheng J, Chiarella J, et al. (2016) HIV drug resistance mutations (DRMs) detected by deep sequencing in virologic failure subjects on therapy from Hunan province, China. *PLoS One* 11: e0149215.
7. Liao L, Xing H, Su B, Wang Z, Ruan Y, et al. (2012) Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China. *AIDS* 27: 1815-1824.
8. Moore DM, Zhang W, Yip B, Genebat M, Lima VD, et al. (2010) Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. *HIV Med* 11: 299-307.
9. Boyer S, Clerc I, Bonono CR, Marcellin F, Bilé PC, et al. (2011) Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: Individual and healthcare supply-related factors. *Social Science and Medicine* 72: 1383-1392.
10. Machado-Alba JE, González-Santos DM, Vidal-Guitart X (2011) Effectiveness of antiretroviral treatment in patients from Pereira and Manizales. *Rev Salud Publica (Bogota)* 13: 492-503.
11. Glass TR, De Geest S, Weber R, Vernazza PL, Rickenbach M, et al. (2006) Correlates of self-reported non-adherence to antiretroviral therapy in HIV-infected patients: The Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr* 41: 385-392.
12. Glass TR, Sterne JA, Schneider MP, De Geest S, Nicca D, et al. (2015) Self-reported non-adherence to antiretroviral therapy as a predictor of viral failure and mortality. *AIDS* 29: 2195-2200.
13. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, et al. (2010) Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: A cross-sectional study in Soweto, South Africa. *AIDS* 24: 1679-1687.
14. Carrieri MP, Raffi F, Lewden C, Sobel A, Michelet C, et al. (2003) Impact of early versus late adherence to highly active antiretroviral therapy on immunovirological response: A 3 year follow-up study. *Antivir Ther* 8: 585-594.

15. Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K (2008) Predictors of adherence to antiretroviral therapy among HIV-infected persons: A prospective study in Southwest Ethiopia. *BMC Public Health* 8: 265.
16. Tessema B, Biadlegne F, Mulu A, Getachew A, Emmrich F, et al. (2010) Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: A cross-sectional study. *AIDS Res Ther* 7: 2.
17. Olowookere SA, Fatiregun AA, Akinyemi JO, Bamgboye AE, Osagbemi GK (2008) Prevalence and determinants of nonadherence to highly active antiretroviral therapy among people living with HIV/AIDS in Ibadan, Nigeria. *The Journal of Infection in Developing Countries* 2: 369-372.
18. Pefura-Yone EW, Soh E, Kengne AP, Balkissou AD, Kuaban C (2013) Non-adherence to antiretroviral therapy in Yaounde: Prevalence, determinants and the concordance of two screening criteria. *Journal of Infection and Public Health* 6: 307-315.
19. Yuan Y, Xing H, Wang XY, Liu CH, Yang LT, et al. (2011) The prevalence of HIV-1 drug resistance and associated factors in AIDS patients receiving HAART in Zhecheng county, Henan province. *Zhonghua Yu Fang Yi Xue Za Zhi* 45: 619-624.
20. Byakika-Tusiime J OJ, Tumwikirize WA, Katabira ET, Mugenyi PN, Bangsberg DR (2005) Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. *International Journal of STD and AIDS* 16: 38-41.
21. Carballo E C-SC, Carrera I, Fraga J, De La Fuente J, Ocampo A, et al. (2004) Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. *Qual Life Res* 13: 587-589.
22. Murri R AA, Trotta MP, De Luca A, Melzi S, Minardi C, et al. (2004) Patient-reported and physician-estimated adherence to HAART: Social and clinic center-related factors are associated with discordance. *J Gen Intern Med* 19: 1104-1110.
23. Carrieri MP, Lepout C, Protopopescu C, Cassuto JP, Bouvet E, et al. (2006) Factors associated with nonadherence to highly active antiretroviral therapy: A 5 year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. *J Acquir Immune Defic Syndr* 41: 477-485.
24. Wakibi SN, Ng'ang'a ZW, Mbugua GG (2011) Factors associated with non-adherence to highly active antiretroviral therapy in Nairobi, Kenya. *AIDS Res Ther* 8: 43.
25. Beyene KA, Gedif T, Gebre-Mariam T, Engidawork E (2009) Highly active antiretroviral therapy adherence and its determinants in selected hospitals from south and central Ethiopia. *Pharmacoepidemiol Drug Saf* 18: 1007-1015.
26. Wasti SP, Simkhada P, Randall J, Freeman JV, van Teijlingen E (2012) Factors influencing adherence to antiretroviral treatment in Nepal: A mixed-methods study. *PLoS One* 7: e35547.
27. Tsega B, Srikanth BA, Shewamene Z (2015) Determinants of non-adherence to antiretroviral therapy in adult hospitalized patients, Northwest Ethiopia. *Patient Prefer Adherence* 9: 373-380.
28. Eholié S-P, Tanon A, Polneau S, Ouiminga M, Djadjji A, et al. (2007) Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Côte d'Ivoire. *J Acquir Immune Defic Syndr* 45: 355-358.
29. Parruti G, Manzoli L, Toro PM, D'Amico G, Rotolo S, et al. (2006) Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: Predictors and impact on virologic response and relapse. *AIDS Patient Care and STDs* 20: 48-56.
30. Peretti-Watel P, Spire B, Schiltz MA, Bouhnik AD, Heard I, et al. (2006) Vulnerability, unsafe sex and non-adherence to HAART: Evidence from a large sample of French HIV/AIDS outpatients. *Social Science and Medicine* 62: 2420-2433.
31. Bonolo PdF, Ceccato MdGB, Rocha GM, Acúrcio FdA, Campos LN, et al. (2013) Gender differences in non-adherence among Brazilian patients initiating antiretroviral therapy. *Clinics (Sa-o Paulo, Brazil)* 68: 612-620.
32. Barclay TR, Hinkin CH, Castellon SA, Mason KI, Reinhard MJ, et al. (2007) Age-associated predictors of medication adherence in HIV-positive adults: Health beliefs, self-efficacy and neurocognitive status. *Health psychology* 26: 40-49.
33. Silva MrCF, Ximenes RADA, Miranda Filho DcB, Arraes LWDMS, Mendes M, et al. (2009) Risk-factors for non-adherence to antiretroviral therapy. *Revista do Instituto de Medicina Tropical de Sao Paulo* 51: 135-139.
34. Ka A, Okojie O, Oqua D, Rc K, Omonaiye O, et al. (2011) Medication adherence and risk factors for non-adherence among patients taking highly active antiretroviral therapy. *West African Journal of Pharmacy* 22: 19-26.
35. Nakimuli-Mpungu E (2009) Psychological distress as a risk factor for non-adherence to highly active anti-retroviral therapy. 11th Anniversary Annual International Meeting of the Institute of Human Virology Baltimore, MD United States 51: 155.
36. Pennap GR, Abdullahi U, Bako Ia (2013) Adherence to highly active antiretroviral therapy and its challenges in people living with human immunodeficiency virus (HIV) infection in Keffi, Nigeria. *Journal of AIDS and HIV Research* 5: 52-28.
37. Tadios Y, Davey G (2006) Antiretroviral treatment adherence and its correlates in Addis Ababa, Ethiopia. *Ethiopian Medical Journal* 44: 237-244.
38. Mitiku H, Abdosh T, Teklemariam Z (2013) Factors affecting adherence to antiretroviral treatment in harari national regional state, eastern Ethiopia. *ISRN AIDS* 2013: 960954.
39. Baltazary G, Akarro RRJ, Mussa AS (2011) Some factors associated with non-adherence to antiretroviral therapy (ART) in people living with HIV/AIDS (PLHA) in Tanzania: A case study of Dar es Salaam region. *East African Journal of Public Health* 8: 237-246.
40. Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, et al. (2009) Factors associated with non-adherence to long-term highly active antiretroviral therapy: A 10 year follow-up analysis with correction for the bias induced by missing data. *J Antimicrob Chemother* 64: 599-606.
41. Bonolo PdF, César CC, Acúrcio FA, Ceccato MdGB, de Pádua CAM, et al. (2005) Non-adherence among patients initiating antiretroviral therapy: A challenge for health professionals in Brazil. *AIDS* 19: S5-S13.
42. Applebaum AJ, Richardson MA, Brady SM, Brief DJ, Keane TM (2009) Gender and other psychosocial factors as predictors of adherence to highly active antiretroviral therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substance-related disorder. *AIDS and Behavior* 13: 60-65.
43. Silva JAG, Dourado I, Brito Amd, Silva CALd (2015) Factors associated with non-adherence to antiretroviral therapy in adults with AIDS in the first six months of treatment in Salvador, Bahia State, Brazil. *Cadernos de saude publica* 31: 1188-1198.
44. Jaquet A, Ekouevi DK, Bashi J, Aboubakrine M, Messou E, et al. (2010) Alcohol use and non-adherence to antiretroviral therapy in HIV-infected patients in West Africa. *Addiction* 105: 1416-1421.
45. Idindili B, Jullu B, Mugusi F, Tanner M (2012) A case-control study of factors associated with non-adherent to antiretroviral therapy among HIV infected people in Pwani Region, eastern Tanzania. *Tanzania Journal of Health Research* 14.
46. Morojele NK, Kekwaletswe CT, Nkosi S (2014) Associations between alcohol use, other psychosocial factors, structural factors and antiretroviral therapy (ART) adherence among South African ART recipients. *AIDS and Behavior* 18: 519-524.
47. Venkatesh KK, Srikrishnan AK, Mayer KH, Kumarasamy N, Raminani S, et al. (2010) Predictors of nonadherence to highly active antiretroviral therapy among HIV-infected South Indians in clinical care: Implications for developing adherence interventions in resource-limited settings. *AIDS Patient Care STDS* 24: 795-803.
48. Royal SW, Kidder DP, Patrabanish S, Wolitski RJ, Holtgrave DR, et al. (2009) Factors associated with adherence to highly active antiretroviral therapy in homeless or unstably housed adults living with HIV. *AIDS Care* 21: 448-455.
49. Olisah VO, Baiyewu O, Sheikh TL (2010) Adherence to highly active antiretroviral therapy in depressed patients with HIV/AIDS attending a Nigerian university teaching hospital clinic. *African Journal of Psychiatry* 13: 275-279.
50. Kleinman NJ, Manhart LE, Mohanraj R, Kumar S, Jeyaseelan L, et al. (2015) Antiretroviral therapy adherence measurement in non-clinical settings in South India. *AIDS Care* 27: 248-254.

**Citation:** Dibaba B, Hussein M (2017) Factors Associated with Non-Adherence to Antiretroviral Therapy among Adults living with HIV/AIDS in Arsi Zone, Oromia. *J AIDS Clin Res* 8: 647. doi:[10.4172/2155-6113.1000647](https://doi.org/10.4172/2155-6113.1000647)